

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
<input type="checkbox"/>	<input checked="" type="checkbox"/> The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
<input type="checkbox"/>	<input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
<input type="checkbox"/>	<input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/> A description of all covariates tested
<input checked="" type="checkbox"/>	<input type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
<input checked="" type="checkbox"/>	<input type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
<input checked="" type="checkbox"/>	<input type="checkbox"/> For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
<input checked="" type="checkbox"/>	<input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
<input checked="" type="checkbox"/>	<input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	-SlideBook v.6.0 (3i-Intelligent Imaging) was used to acquire confocal fluorescent images of Legionella-infected Hek293T cells. -Image Studio v.5.2 (LI-COR Biosciences) was used to acquire western blots. -Mass spec data were acquired using Orbitrap Fusion Lumos Tribrid Mass Spectrometer (catalog no. IQLAAEGAAPFADBMBHQ; Thermo Scientific).
Data analysis	-Confocal fluorescent images were contrasted, overlaid and analyzed using ImageJ v.1.53 (NIH). -Western blots were contrasted using Image Studio v.5.2 (LI-COR Biosciences). -Mass specs spectra were recorded using Thermo Xcalibur Software v.4.4 (catalog no. OPTON-30965; Thermo Scientific) and Tune application v.3.0 (Thermo Scientific). Raw files were searched using Proteome Discoverer Software 2.3. Spectra were searched with the SEQUEST HT or Comet (v.2019.01.1) search engine. Figures in the text were prepared in Adobe Illustrator.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Data is available from the corresponding author at the reader's request.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Reporting on race, ethnicity, or other socially relevant groupings

Population characteristics

Recruitment

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Data exclusions

Replication

Randomization

Blinding

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

1. Rabbit polyclonal anti-Legionell, home made; dilution 1:500 for immunofluorescence.
2. mouse monoclonal anti-HA, Sigma-Aldrich, Cat# H9658; dilution 1:1000 for immunofluorescence; dilution 1:10000 for Western blot.
3. Mouse monoclonal anti-ubiquitin, clone P4D1, BioLegend, Cat# 646302; dilution 1:2000 for Western blot.
4. Rabbit polyclonal anti-Flag, Proteintech, Cat# 20543-1-AP; dilution 1:2000 for Western blot.
5. Alexa Fluor 488-conjugated Donkey anti-Rabbit IgG, Invitrogen, Cat# A-21206; dilution 1:1000 for immunofluorescence.
6. Alexa Fluor 488-conjugated Donkey anti-mouse IgG, Invitrogen, Cat# A-21202; dilution 1:1000 for immunofluorescence.
7. Alexa Fluor 568-conjugated Donkey anti-Rabbit IgG, Invitrogen, Cat# A-10042; dilution 1:1000 for immunofluorescence.
8. Alexa Fluor 647-conjugated Donkey anti-Rabbit IgG, Invitrogen, Cat# A-31573; dilution 1:1000 for immunofluorescence.
9. Alexa Fluor 680-conjugated Donkey anti-mouse IgG, Invitrogen, Cat# A-10038; dilution 1:10000 for Western blot.
10. Donkey anti-rabbit RDye 800CW IgG, LI-COR, Cat# 926-32213; dilution 1:10000 for Western blot.

Validation

All antibodies were validated by Western blot for specificity and validation reports of the commercially available antibodies are provided on the manufacturer's website:

1. PMID: 31682223; PMID: 31690664.
2. <https://www.sigmaaldrich.com/US/en/product/sigma/h9658>
3. <https://www.biolegend.com/en-us/products/purified-anti-ubiquitin-antibody-6021>
4. <https://www.ptglab.com/products/Flag-Tag-Antibody-20543-1-AP.htm>
5. <https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21206>
6. <https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A21202>
7. <https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A10042>
8. <https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-31573>
9. <https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A10038>
10. <https://www.licor.com/bio/reagents/irdye-800cw-donkey-anti-rabbit-igg-secondary-antibody>

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

Hek293T cells

Authentication

Cell lines used were not authenticated by researchers in this study.

Mycoplasma contamination

Cell lines were routinely tested for mycoplasma contamination by mycoplasma detection kit and confirmed that they were negative for mycoplasma contamination.

Commonly misidentified lines
(See [ICLAC](#) register)

No commonly misidentified cell lines were used.